Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $220.31 USD
Change Today -8.52 / -3.72%
Volume 1.8M
VRX On Other Exchanges
Symbol
Exchange
Toronto
New York
Mexico
Frankfurt
As of 8:04 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Snapshot

Open
$225.71
Previous Close
$228.83
Day High
$227.33
Day Low
$219.56
52 Week High
05/28/15 - $246.01
52 Week Low
08/11/14 - $106.00
Market Cap
75.1B
Average Volume 10 Days
1.7M
EPS TTM
$2.75
Shares Outstanding
340.9M
EX-Date
11/10/10
P/E TM
80.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for VALEANT PHARMACEUTICALS INTE (VRX)

valeant pharmaceuticals inte (VRX) Details

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

16,800 Employees
Last Reported Date: 02/25/15
Founded in 1983

valeant pharmaceuticals inte (VRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.9M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $953.8K
President of Valeant Europe and General Manag...
Total Annual Compensation: $499.3K
Executive Vice President and Company Group Ch...
Total Annual Compensation: $5.8M
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $715.4K
Compensation as of Fiscal Year 2014.

valeant pharmaceuticals inte (VRX) Key Developments

Valeant Reportedly Made A Preliminary Approach To Buy Zoetis

Valeant Pharmaceuticals International, Inc. (TSX:VRX) has made a preliminary approach to buy Zoetis Inc. (NYSE:ZTS), people familiar with the matter said. The shares of Zoetis rose 11% after the rumour to close at $55.38.

Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR®

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that Valeant submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. RELISTOR is a peripherally acting mu-opioid receptor antagonist specifically designed to block the constipating effects of opioid pain medications in the gastrointestinal tract. RELISTOR does not cross the blood-brain barrier, therefore relieving the distressing effects of the constipation without affecting the analgesic effect of the opioid. RELISTOR Subcutaneous Injection has been FDA approved since 2008 to treat OIC in patients with advanced illness who are receiving palliative care, and was approved in 2014 for the treatment of OIC in patients with chronic non-cancer pain.

Valeant Pharmaceuticals International, Inc. Presents at Piper Jaffray Heartland Summit, Jun-23-2015

Valeant Pharmaceuticals International, Inc. Presents at Piper Jaffray Heartland Summit, Jun-23-2015 . Venue: Minneapolis, Minnesota, United States. Speakers: J. Michael Pearson, Chairman and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $220.31 USD -8.52

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.01 USD -0.96
Astellas Pharma Inc ¥1,746 JPY +2.50
Celgene Corp $114.91 USD -3.01
Mylan NV $67.63 USD -1.43
Sun Pharmaceutical Industries Ltd 874.60 INR +25.05
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings 78.0x
Price/Sales 9.0x
Price/Book 12.2x
Price/Cash Flow 31.5x
TEV/Sales 5.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit www.valeant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.